[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:idh1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"IDH1 Gene",45,39,[8,16,23,30,36,43,49,55,61,67,73,79,85,91,97,103,110,115,121,127,133,139,145,151,157,163,169,175,181,187,193,199,205,210,216,221,227,232,238,244,251,257,263,270,276],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05401097","IDH Targeted\u002FNon- Targeted vs Non-targeted\u002FIDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)",[12],"Phase 2","RECRUITING","2026-08-26T02:15:30.699880Z","2026-07-05T05:32:16.798999Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07215910","Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer",[20],"Phase 3","2026-08-26T02:18:03.638950Z","2026-06-17T02:29:30.057250Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06501625","Ivosidenib Plus Durvalumab and Gemcitabine\u002FCisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation",[27],"Phase 1\u002FPhase 2","2026-08-26T02:16:42.787115Z","2026-05-29T15:36:40.175966Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07304011","Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent",[12],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:29.666379Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT07104799","Momelotinib During and After HCT in Myelofibrosis",[40],"Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.498826Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06465953","Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation",[20],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.321717Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06445959","Phase 1b\u002F2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib",[27],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:29.294355Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05588141","A Phase I\u002FII Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations",[27],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.163159Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07130695","Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation",[40],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:28.846320Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05345002","All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma",[12],"2026-08-26T02:18:16.220328Z","2026-05-05T02:43:28.803848Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07392242","A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia",[12],"2026-08-26T02:17:40.683658Z","2026-05-05T02:43:28.651371Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT03922555","ASTX727 in Recurrent\u002FProgressive Non-enhancing IDH Mutant Gliomas",[40],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.502498Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06285890","Phase I Study of HC-7366 for Acute Myeloid Leukemia",[40],"2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.182174Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07006688","A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment",[40],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:28.011880Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05917145","ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma",[40],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.925233Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":108,"content_modified":109},"NCT06552260","A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma",[107],"Early Phase 1","2026-08-26T02:17:46.653867Z","2026-05-05T02:43:27.831514Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":65,"content_modified":114},"NCT06707493","Ivosidenib as Post-HSCT Maintenance for AML",[12],"2026-05-05T02:43:27.795402Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07471841","Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax",[12],"2026-08-26T02:18:20.384845Z","2026-05-05T02:43:27.746285Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT05756777","A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)",[40],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.248629Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07011004","A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia",[40],"2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.130925Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06666712","Chronic CED of TPT for Recurrent Malignant Glioma",[40],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:26.959232Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06484062","Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes",[40],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:26.737999Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT04774393","Decitabine\u002FCedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[27],"2026-08-26T02:16:23.080181Z","2026-05-05T02:35:31.777743Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05873686","A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers",[40],"2026-08-26T02:17:00.709807Z","2026-07-19T19:36:05.121267Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT06566742","A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic\u002FSyndromes\u002FChronic Myelomonocytic Leukemia.",[12],"2026-08-26T02:18:38.077159Z","2026-07-19T19:36:05.036073Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT06668584","A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies",[12],"2026-08-26T02:19:02.550788Z","2026-05-05T02:47:14.264276Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia",[12],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:29.732946Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT04493164","CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[12],"2026-08-26T02:15:01.639696Z","2026-05-05T02:43:29.153694Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[40],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05303519","SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)",[20],"2026-08-26T02:18:51.009190Z","2026-05-05T02:43:27.742731Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT02074839","Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation",[40],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:27.599227Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":179,"content_modified":209},"NCT06543381","Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant",[40],"2026-04-29T02:57:57.159415Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT06161974","Study of Olutasidenib and Temozolomide in HGG",[12],"2026-08-26T02:17:51.502023Z","2026-07-05T05:32:16.747418Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":149,"content_modified":220},"NCT07223034","A Study of 177Lu-PSMA-617 in People With Gliomas",[40],"2026-07-05T05:32:16.669055Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":225,"content_modified":226},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[27],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":173,"content_modified":231},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",[40],"2026-05-05T02:43:27.513961Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT03471260","Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies",[27],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.087679Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":161,"content_modified":243},"NCT07486713","Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies",[242],"Phase 4","2026-05-05T02:43:29.588444Z",{"nct_id":245,"title":246,"phases":247,"status":248,"updated_at":249,"content_modified":250},"NCT07629089","VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and\u002For IDH2 Mutations",[40],"NOT_YET_RECRUITING","2026-08-26T02:16:44.178623Z","2026-06-06T00:48:49.532698Z",{"nct_id":252,"title":253,"phases":254,"status":248,"updated_at":255,"content_modified":256},"NCT07411586","Phase 1\u002F1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia",[40],"2026-08-03T03:11:12.615114Z","2026-05-05T02:43:26.718345Z",{"nct_id":258,"title":259,"phases":260,"status":248,"updated_at":261,"content_modified":262},"NCT07219199","Residual IDH1-Mutant Tumor Cell Quantification Study",[],"2026-08-26T02:16:22.235886Z","2026-05-05T02:43:27.664599Z",{"nct_id":264,"title":265,"phases":266,"status":267,"updated_at":268,"content_modified":269},"NCT02704858","Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.295234Z",{"nct_id":271,"title":272,"phases":273,"status":267,"updated_at":274,"content_modified":275},"NCT06445907","Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia",[40],"2026-08-03T01:57:10.726985Z","2026-05-05T02:43:27.037954Z",{"nct_id":277,"title":278,"phases":279,"status":267,"updated_at":280,"content_modified":281},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]